daily oral glp-1 receptor agonist orforglipron for adults with obesity Pill Approved by FDA Learn about Orforglipron a weight

How long can I stay on a GLP-1 medication

CVD, cardiovascular disease

It is estimated that upwards of 30 million Americans will be on GLP-1 treatment in 2030 (an increase of 10 million from those on branded GLP-1s in 2026), making the growth of GLP-1s one of the key storylines to watch in the new year

A Double-Blind Randomised Controlled Trial Testing the Effect of a Barley Product Containing Varying Amounts and Types of Fibre on the Postprandial Glucose Response of Healthy Volunteers

Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial

Bariatric surgery and GLP-1 medications are taking the world by a storm right now not just because of their availability and effectiveness with helping with long-term obesity management and managing health crises related to weight